Accepted Manuscript

Adverse Psychiatric Effects of Disease-Modifying Therapies in Multiple Sclerosis: A Systematic Review

Majid Gasim, Charles N. Bernstein, Lesley A. Graff, Scott B. Patten, Renee El-Gabalawy, Jitender Sareen, James M. Bolton, James J Marriott, John D. Fisk, R.A. Marrie, for the CIHR team "Defining the burden and managing the effects of psychiatric comorbidity in chronic inflammatory disease"

PII: S2211-0348(18)30320-1


DOI: https://doi.org/10.1016/j.msard.2018.09.008

Reference: MSARD 963

To appear in: Multiple Sclerosis and Related Disorders

Received date: 8 May 2018 Revised date: 16 July 2018

Accepted date: 10 September 2018




This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Highlights:

- Depression was the most common adverse psychiatric effect reported in disease-modifying therapy studies.
- None of the disease-modifying therapies studied were associated with an increased risk of adverse psychiatric effects.





Download English Version:

https://daneshyari.com/en/article/10212451

Download Persian Version:

https://daneshyari.com/article/10212451

<u>Daneshyari.com</u>